Demenz und Demenzerkrankung

Zusammenfassung

Aufgrund der steigenden Lebenserwartung werden 1/4 aller Menschen in Deutschland eine Demenz entwickeln. Zumeist sind neurodegenerative Veränderungen die Ursache der Demenz. Die Alzheimer-Erkrankung ist bei mehr als 60% der Fälle die alleinige Ursache, in weiteren 10–20% im Zusammenspiel mit vaskulären Läsionen. Die Diagnostik neurodegenerativer Veränderungen ist in den letzten 10 Jahren insbesondere durch PET-Untersuchungen bereits in einem Frühstadium mit hoher Sicherheit möglich. Die Bedeutung nuklearmedizinischer Verfahren wird mit der laufenden Entwicklung von Interventionen, die an der molekularen Kaskade neurodegenerativer Erkrankung ansetzen, deutlich zunehmen.

Abstract

Due to the rise of live expectency dementia will develope in 1/4 of all persons in Germany. Neurodegenerative changes are the main cause of dementia. Alzheimer's disease is involved in more than 60% of all cases exclusively and in further 10–20% together with vascular lesions. The diagnosis of neurodegenerative changes has been improved during the last 10 years. Especially PET investigations allow a high degree of correct diagnosis in the early stages of dementia. The value of nuclear medicine will increase with the advent of new interventions which target the molecular pathology of neurodegenerative diseases.

Schlüsselwörter

Demenz - Diagnose - FDG-PET - Amyloid-PET

Key words

dementia - diagnosis - FDG-PET - amyloid-PET

• Literatur

• 1 Alzheimer’s Association . 2012 Alzheimer’s disease facts and figures. Alzheimers Dement 2012; 8: 131-168
• 2 Ballard C, Gauthier S, Corbett A et al. Alzheimer’s disease. Lancet 2011; 377: 1019-1031
• 3 Bickel H. Demenzsyndrom und Alzheimer Krankheit: Eine Schätzung des Krankenbestandes und der jährlichen Neuerkrankungen in Deutschland. Gesundheitswesen 2000; 60: 211-218
• 4 Blendon RJ, Benson JM, Weldon KJ. Harvard Public School of Health Surveys. Alzheimer Europe Five Country Survey: Germany 2011;
• 5 Cairns NJ, Bigio EH, Mackenzie IR et al. Consortium for Frontotemporal Lobar Degeneration. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007; 114: 5-22
• 6 Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-340
• 7 Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127
• 8 Eschweiler GW, Leyhe T, Klöppel S et al. New developments in the diagnosis of dementia. Dtsch Arztebl Int 2010; 107: 677-683
• 9 Gorno-Tempini ML, Hillis AE, Weintraub S et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014
• 10 Hüll M, Schmidtke K. Normales versus pathologisches kognitives Altern. Kognitive Veränderungen im Alter: was ist normal?. Neurologe & Psychiater 2007; 10: 42-48
• 11 Imbimbo BP, Giardina GA. γ-secretase inhibitors and modulators for the treatment of Alzheimer’s disease: disappointments and hopes. Curr Top Med Chem 2011; 11: 1555-1570
• 12 Jack Jr CR, Knopman DS, Weigand SD et al. An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol 2011; DOI: 10.1002/ana.22628. [Epub ahead of print]
• 13 Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011; 32 (Suppl. 01) S20-S36
• 14 Leicht H, Heinrich S, Heider D et al. AgeCoDe study group . Net costs of dementia by disease stage. Acta Psychiatr Scand 2011; 124: 384-395
• 15 Luengo-Fernandez R, Leal J, Gray AM. Cost of dementia in the pre-enlargement countries of the European Union. J Alzheimers Dis 2011; 27: 187-196
• 16 Mollenhauer B, Förstl H, Deuschl G et al. Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int 2010; 107: 684-691
• 17 Rinne JO, Brooks DJ, Rossor MN et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372
• 18 Scheinin NM, Scheinin M, Rinne JO. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer’s disease. Q J Nucl Med Mol Imaging 2011; 55: 265-279
• 19 Schneider JA, Aggarwal NT, Barnes L et al. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 2009; 18: 691-701
• 20 Small GW, Siddarth P, Kepe V et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012; 692: 215-222
• 21 Taylor R. Alzheimer und ich. Verlag Huber; Bern: 2011
• 22 van Harten AC, Kester MI, Visser PJ et al. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 2011; 49: 353-366
• 23 Wiltfang J, Lewczuk P, Riederer P et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005; 6: 69-84